Rastogi S, Guerrero M, Wang M, Ilsar I, Sabbah MS, Gupta RC, Sabbah HN. Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs. Am J Physiol Heart Circ Physiol 300: H1501-H1509, 2011. First published January 7, 2011 doi:10.1152/ajpheart.00636.2010.-This study examined the effects of localized intramyocardial injections of hepatocyte growth factor (HGF) naked DNA plasmid on the progression of left ventricular (LV) dysfunction and remodeling in dogs with moderate heart failure (HF). Twenty-one dogs with intracoronary microembolization-induced HF [LV ejection fraction (EF) ϭ 35-40%] were randomized into three treatment groups, namely, high-dose HGF plasmid (4.0 mg, n ϭ 7), low-dose HGF plasmid (0.4 mg, n ϭ 7), and shamoperated controls treated with normal saline (n ϭ 7). A total of 10 -15 injections of HGF plasmid or saline were made directly into the anterior wall of LV. LV EF and end-systolic volume (ESV) were measured before randomization (pretreatment) and at the end of 3 mo of follow-up (posttreatment). Treatment effect (⌬) was calculated as the change from pre-to posttreatment. Protein expression of sarcoplasmic reticulum (SR) Ca 2ϩ -cycling proteins was determined in LV tissue obtained from the sites of HGF injection and remote areas. Low-dose HGF attenuated the decline in EF (⌬EF: Ϫ3 Ϯ 1 vs. Ϫ8 Ϯ 1%, P Ͻ 0.05) and the increase in ESV (⌬ESV: 6 Ϯ 2 vs. 10 Ϯ 1 ml, P Ͻ 0.05) seen in control sham-operated dogs, whereas high-dose HGF significantly increased EF (⌬EF: 4 Ϯ 1 vs. Ϫ8 Ϯ 1%, P Ͻ 0.05) and prevented the increase in ⌬ESV (ESV: Ϫ1 Ϯ 1 vs. 10 Ϯ 1 ml, P Ͻ 0.05) compared with control dogs. Treatment with high-and low-dose HGF improved the expression of the SR Ca 2ϩ -cycling proteins compared with controls. In conclusion, regional intramyocardial injections of HGF naked DNA plasmid improve regional and global LV function and prevent progressive LV remodeling. ventricular function and remodeling; sarcoplasmic calcium-cycling regulatory proteins HEPATOCYTE GROWTH FACTOR (HGF) is a pluripotent growth factor that possesses a remarkable ability to promote tissue repair and organ regeneration after injury, as well as an agent for amelioration of tissue fibrosis and dysfunction in chronic conditions. HGF was initially purified and cloned as a potent mitogen for hepatocytes. It has been demonstrated to exert mitogenic, motogenic, and morphogenic activities in various cell types. All the known biological effects of HGF are mediated by the interaction with its specific receptor, c-Met (4).
ventricular function and remodeling; sarcoplasmic calcium-cycling regulatory proteins HEPATOCYTE GROWTH FACTOR (HGF) is a pluripotent growth factor that possesses a remarkable ability to promote tissue repair and organ regeneration after injury, as well as an agent for amelioration of tissue fibrosis and dysfunction in chronic conditions. HGF was initially purified and cloned as a potent mitogen for hepatocytes. It has been demonstrated to exert mitogenic, motogenic, and morphogenic activities in various cell types. All the known biological effects of HGF are mediated by the interaction with its specific receptor, c-Met (4) .
The existence of a local cardiac HGF system (HGF/c-MET) has been demonstrated in animal models of cardiac ischemia and reperfusion (15) , suggesting a potential role for HGF in cardiovascular diseases. Plasma concentration of HGF is elevated in the early stage after acute myocardial infarction (AMI) (24) . In patients, enhanced secretion of HGF from the infarct region has been associated with less severe ventricular enlargement and improved cardiac function (25) . Augmented expression of the c-Met receptor also has been observed in cardiac myocytes isolated from the viable border region 24 h after AMI (24) , suggesting that cardiac myocytes may become target cells of HGF in response to AMI.
HGF also has been shown to possess a host of properties that include angiogenesis, stem cell mobilization, and antifibrotic, antiapoptotic, and antihypertrophic effects (12, 23) . In cultured human fibroblasts, as well as in cardiomyopathic hamsters, an increased HGF concentration resulted in the stimulation of the degradation pathway and the inhibition of the synthetic pathway of the extracellular matrix (23) . This potent antifibrotic effect has been confirmed by several investigations. A growing burden of evidence suggests that HGF may exert a cardioprotective role in the early phase of AMI, limiting postinfarction early remodeling (13) , but the chronic effects of HGF on the progression of HF are still not completely understood. Acting in concert, these benefits, triggered by HGF, can contribute to the improvement of left ventricular (LV) function and the attenuation of progressive LV remodeling in heart failure (HF). In the present study, we investigated the effects of localized intramyocardial injections of naked DNA plasmid encoding HGF on the progression of LV dysfunction and remodeling in dogs with moderate HF produced by intracoronary microembolizations (21) .
METHODS
Experimental model. The canine model of chronic HF used in this study was previously described in detail (21) . In this preparation, LV dysfunction was produced by multiple sequential intracoronary microembolizations that result in loss of viable myocardium. The model manifests many of the sequelae of HF observed in humans, including marked and progressive depression of LV systolic and diastolic function, reduced cardiac output, and increased LV filling pressures. In the present study, 21 healthy mongrel dogs, weighing between 19.4 and 28.2 kg, underwent serial coronary microembolizations to produce HF. Embolizations were performed 1-2 wk apart and were discontinued when LV ejection fraction (EF), determined by ventriculography, was between 35 and 40%. The cardiac catheterization procedures were performed under general anesthesia and sterile conditions. The anesthesia regimen consisted of intravenous oxymorphone hydrochloride (0.22 mg/kg) and diazepam (0.17 mg/kg) for induction, and a plane of anesthesia was maintained with 1-2% isoflurane.
Study protocol and end points. The study was a blinded, randomized, sham-operated placebo-controlled design. Two weeks after the last embolization, 21 dogs were randomized into 3 study groups. One group of dogs (n ϭ 7) was treated with high-dose HGF (total dose of 4.0 mg), a second group of dogs (n ϭ 7) was treated with low-dose HGF (total dose of 0.4 mg), and a third group of dogs (n ϭ 7) was treated with normal saline and served as a placebo sham-operated control. A midsternotomy was performed under general anesthesia, the pericardium was opened, and a total of 10 -15 injections of either HGF or saline were made directly into the anterior wall of the LV. The injections were made ϳ1 cm apart while avoiding the epicardial coronary vessels. A total of 2 ml of HGF plasmid or saline were injected (0.15-0.2 ml per injection). Once the injections were made, the sternum was approximated using steel sutures, the incision was closed in layers using 4-0 vicryl, and the skin was closed using surgical staples. The high dose of 4.0 mg of HGF used in this study was selected based on experiments in normal dogs that showed 2.5-fold increased mRNA expression of HGF and 2.7-fold increased protein expression of HGF in the LV anterior wall that received the injections compared with the LV posterior wall 2 wk after injections (Fig. 1) . Pretreatment hemodynamic, angiographic, and echocardiographic measurements were made before the chest was opened and the HGF or saline injections were performed (2 wk after the last embolization) and were repeated at 3 mo after the injections were made. After the final 3 mo of physiological studies were completed, the hearts were removed via a thoracotomy under general anesthesia and the tissue was prepared for histological and biochemical evaluation. LV tissue samples were also obtained from seven normal dogs for comparisons. All normal dogs had a normal two-dimensional echocardiogram of the heart, a LV EF Ͼ50%, and a normal electrocardiogram.
The study primary end points were: 1) change in global LV EF determined angiographically, 2) changes in LV end-systolic volume (ESV) determined angiographically, and 3) changes in regional LV wall motion determined from LV end-systolic and end-diastolic angiographic silhouettes. The study was approved by the Henry Ford Health System Institutional Animal Care and Use Committee and adheres to the American Physiological Society's "Guiding Principles for Research Involving Animals and Human Beings" (2) .
Hemodynamic, ventriculographic, and echocardiographic measurements. Hemodynamic and angiographic measurements were made at baseline, before any microembolization, at the time of randomization, before initiation of therapy (pretreatment), and at the end of 3 mo of therapy (posttreatment). Aortic and LV pressures were measured with catheter-tip micromanometers (Millar Instruments, Houston, TX). Other hemodynamic indexes included cardiac output (CO), stroke volume (SV), cardiac index (CI), and LV end-diastolic circumferential wall stress (EDWS) determined as described previously (21, 26) . Left ventriculograms were obtained with the dog placed on its right side and were recorded on 35-mm cinefilm at 30 frames/s during the injection of 20 ml of contrast material (RENO-M-60; Squibb, Princeton, NJ). Correction for image magnification was made with a radiopaque calibrated grid placed at the level of the LV. LV ESV and end-diastolic volume (EDV) were calculated from LV silhouettes using the area-length method, and LV EF was calculated as previously described (22) . SV was calculated as the difference between LV ESV and EDV. CO was calculated as the product of SV and heart rate (HR). Extrasystolic and postextrasystolic beats were excluded from any of the angiographic analysis.
Regional wall motion was determined as the percent segmental systolic shortening (PSSS) and was measured from LV end-systolic and end-diastolic silhouettes obtained before (pretreatment) and after 3 mo of therapy (posttreatment). PSSS was assessed using the rectilinear system whereby the LV silhouettes were divided into six segments: anterobasal (AB), anterolateral (AL), anteroapical (AA), posteroapical (PA), posterolateral (PL), and posterobasal (PB). This is accomplished by constructing lines perpendicular to the LV major axis that divide the major axis into six segments. For each segment, PSSS was calculated as the end-diastolic area minus the end-systolic area, divided by the end-diastolic area times 100.
Echocardiographic studies were performed in all dogs at all specified study time points using a 77020A ultrasound system (HewlettPackard) with a 2.5 MHz transducer. All echocardiographic measurements were made with the dog placed in the right lateral decubitus position and were recorded on a Panasonic 6300 VHS recorder for subsequent off-line analysis. Short-axis two-dimensional echocardiograms obtained at the level of the papillary muscle were used to Values are means Ϯ SE; n ϭ 7 for control dogs and dogs treated with low-or high-dose hypatocyte growth factor (HGF). LV, left ventricular; AoP, aortic pressure; EDP, end-diastolic pressure; EDV, end-diastolic volume; ESV, end-systolic volume; FAS, fractional area of shortening; PE/PA, ratio between peak mitral flow velocity in early diastole (PE) and peak mitral inflow velocity during left atrial contraction (PA); EDWS, LV end-diastolic wall stress. calculate global LV fractional area of shortening (FAS). LV thickness of the posterior wall and interventricular septum were measured, summed, and divided by 2 to obtain average LV wall thickness (h), used for calculation of wall stress. LV major and minor semiaxes were measured and used for calculation of LV EDWS. Wall stress was calculated as follows:
2 ), where P is LV end-diastolic pressure, a is LV major semiaxis, b is LV minor semiaxis, and h is LV wall thickness.
Mitral inflow velocity was measured by pulsed-wave Doppler echocardiography. The velocity waveforms were used to calculate the ratio between peak mitral flow velocity in early diastole (PE) and peak mitral inflow velocity during left atrial contraction (PA) and to determine early mitral inflow deceleration time (DT) as previously described (18) .
Histological evaluations. From each heart, three transverse slices (ϳ3 mm thick) were obtained from the basal, middle, and apical LV thirds. From each slice, transmural tissue blocks were obtained and embedded in paraffin blocks. Transmural tissue blocks were also obtained from the free wall segment of the slice, mounted on cork using Tissue-Tek embedding medium, rapidly frozen in isopentane precooled in liquid nitrogen, and stored at Ϫ70°C until used. Masson's Trichrome staining was used to measure the volume fraction of replacement fibrosis (VFRF) in sections obtained from paraffin blocks. Fluorescent labeling with Griffonia simplicifolia lectin (Vector Labs) was performed to measure interstitial fibrosis (VFIF), myocyte cross-sectional area (MCSA), capillary density (CD), capillaries per fiber, and oxygen diffusion distance (ODD) in 10 randomly selected microscopic fields from each LV wall of each dog in frozen sections, and the results were averaged as previously described (17, 20) . MCSA was used as a measure of cardiomyocyte hypertrophy, and the capillaries-per-fiber ratio was used as an index of capillary density.
Protein expression. Sarcoplasmic reticulum (SR) Ca 2ϩ -cycling regulatory proteins, namely, ryanodine receptor (RyR), phosphorylated RyR (P-RyR), total phospholamban (PLB), phosphorylated PLB at serine 16 (P-PLB16) and threonine 17 (P-PLB17), sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA-2a), and calsequestrin (CSQ) were quantified in sodium dodecyl sulfate-LV homogenate prepared from LV powder by using Western blots as described previously (7, 17) . Band intensity was quantified using a Bio-Rad GS-670 imaging densitometer and expressed as densitometric units, and the percent change from normal dogs was calculated. Antibodies to SERCA-2a, PLB, and CSQ were obtained from Thermo Fisher Scientific (Rockford, IL), and antibodies for RyR, P-RyR, P-PLB16, and P-PLB17 were obtained from Badrilla (Leeds, UK).
mRNA expression. All tissue samples were submitted for analysis without treatment regimen identifiers. mRNA expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the proapoptotic genes caspase-3, poly(ADP-ribose) polymerase (PARP), and BAX, and the antiapoptotic gene BCL2 were measured in LV tissue from all study groups and from normal dogs. Total RNA with an absorbance 
Values are means Ϯ SE; n ϭ 7 for each treatment group. Pre, pretreatment; Post, posttreatment. *P Ͻ 0.05, Pre vs. Post. 
Values are means Ϯ SE; n ϭ 7 for each treatment group. Treatment effect (⌬) was calculated as the change from pre-to posttreatment. NS, not significant. ratio (260 nm/280 nm) above 1.7 was isolated from frozen LV tissue, and ϳ4 -10 g of RNA were reverse-transcribed into cDNA in an assay volume of 80 l as described previously (16) . Band intensities were quantified in densitometric units, and the percent change from normal dogs was calculated. Data analysis. To determine whether differences in hemodynamic, angiographic, echocardiographic, and Doppler variables between study groups were present at baseline, before any coronary microembolizations, and before (pretreatment) HGF injections and randomization, intergroup comparisons were made using one-way analysis of variance (ANOVA) with ␣ set at 0.05. If significance was attained, then pairwise comparisons were performed using the Student-Newman-Keuls test with significance set at P Յ 0.05. Intragroup comparisons of hemodynamic, angiographic, echocardiographic, and Doppler variables within each of the three study groups were made between measurements obtained at pretreatment and after completion of 3 mo of follow-up (posttreatment). For these comparisons, a repeatedmeasures ANOVA was used with ␣ set at 0.05. If significance was achieved by ANOVA, then pairwise comparisons were performed using the Student-Newman-Keuls test with significance set at P Յ 0.05. To assess treatment effect, the change (⌬) in each measurement from pretreatment to posttreatment was calculated for each of the three study arms. Comparisons of changes were made between the placebo sham-operated control group and the two active treatment groups, again using ANOVA with ␣ set at 0.05. If significance was attained, then pairwise comparisons were performed using the Student-Newman-Keuls test with significance set at P Յ 0.05. The statistical analysis for histomorphologic and biochemical measures was conducted using ANOVA with ␣ set at 0.05. If significance was attained, then pairwise comparisons were performed using the Student-Newman-Keuls test with significance set at P Յ 0.05. Linear regression analysis was used for correlations between HR and LV EF and FAS with significance set at P Յ 0.05. All primary and secondary end-point data are means Ϯ SE.
RESULTS
At baseline, all dogs in the study had hemodynamic, ventriculographic, echocardiographic and Doppler findings that were within normal limits for mongrel dogs in our laboratory. Baseline data for all three study groups are shown in Table 1 . There were no significant differences in any of the baseline parameters between HF dogs that were subsequently randomized to placebo or to active treatment with either low-dose or high-dose HGF. Similarly, there were no significant differences among the three study groups with respect to all measures obtained at pretreatment (Table 2) .
Hemodynamic, ventriculographic, echocardiographic, and Doppler observations in placebo sham-operated control dogs.
In placebo-treated sham-operated control dogs, LV EF, FAS, and SV decreased significantly during the 3 mo of follow-up (Table 2 ). This was accompanied by a significant increase in both LV EDV and ESV (Table 2 ). In this study group, LV end-diastolic pressure (EDP) remained elevated and DT decreased significantly, suggesting worsening diastolic function. LV EDWS tended to increase and the ratio PE/PA tended to decrease, providing further support for worsening global LV diastolic function (Table 2) . Values are means Ϯ SE of percent LV segmental systolic shortening; n ϭ 7 for each treatment group. *P Ͻ 0.05, Pre vs. Post.
Hemodynamic, ventriculographic, echocardiographic, and Doppler observation in dogs treated with low-dose HGF.
In dogs treated with low-dose HGF, LV EF decreased significantly, whereas EDV and ESV increased ( Table 2 ). These changes, however, were not as marked as those seen in control dogs ( Table 2 ). In this study cohort, all other global hemodynamic, echocardiographic, and Doppler-derived measures obtained posttreatment were significantly different from measurements made at pretreatment. This suggested that at the very least, low-dose HGF prevented progressive worsening of some global measures of LV systolic and diastolic function and chamber remodeling.
Global hemodynamic, ventriculographic, echocardiographic, and Doppler observation in dogs treated with high-dose HGF.
In dogs treated with high-dose HGF, LV EF, CO, SV, CI, and FAS all increased significantly during the course of 3 mo of therapy (Table 2 ). This increase was accompanied by a modest but significant increase in LV EDV and no change in ESV ( Table  2 ). The LV EDP decreased significantly, as did the LV EDWS, indicating improvement in diastolic function. DT and the ratio PE/PA both tended to increase, giving further credibility to improved global LV diastolic function ( Table 2) .
Comparisons of treatment effect. The ⌬ values and probability values based on comparisons of active treatment groups with sham-operated controls are shown in Table 3 . HR tended to be higher, but not significantly so, in the sham-operated control group compared with either treatment group. Linear regression analysis between the change in HR and the changes in EF and FAS showed no significant correlations (Fig. 2) . Low-dose HGF was not different from controls with respect to mean aortic pressure, LV EDP, CO, EDV, PE/PA, DT, and EDWS. Compared with controls, low-dose HGF significantly improved SV, ESV, LV EF, and FAS but did not improve CI.
High-dose HGF was not different from controls with respect to mean aortic pressure and EDV. Compared with controls, however, high-dose HGF significantly decreased EDP, ESV, and EDWS and increased CO, SV, CI, LV EF, FAS, PE/PA, and DT ( Table 3) .
Effects of HGF therapy on LV segmental wall motion. The results of LV PSSS are shown in Table 4 . In sham-operated controls, PSSS decreased/worsened significantly in all six LV segments at the 3 mo follow-up. In the low-dose HGF group, there were no significant differences posttreatment compared with pretreatment in the AB, AA, and PB segments, but there was a significant decrease in the AL, PA, and PL segments. In the high-dose HGF group, there were no differences in PSSS between pre-and posttreatment values of the AB and PB segments. In this group, however, PSSS increased significantly only in the AL and AA segments in which HGF was administered. In the treatment-effect analysis, comparisons of controls with low-dose HGF elicited no statistically significant differences in all but the AA segment, where the difference was significant in favor of improvement. Compared with controls, high-dose HGF significantly improved PSSS in both the AL and AA segments in which HGF was administered (Table 5) .
Histomorphometric findings. The histomorphometric results in all three study groups are shown in Table 6 . Within-group comparisons between the LV anterior and posterior wall showed no statistically significant differences in any of the measures in the sham-operated control group or the low-dose HGF group. In contrast, there were significant differences between the LV anterior wall and posterior wall in dogs treated with high-dose HGF. In the high-dose HGF group, the anterior wall had significantly less VFRF, less VFIF, greater CD, and significantly shorter ODD and lower MCSA. Comparing the LV anterior wall (treated wall) across groups, the group with 
Values are means Ϯ SE of percent LV segmental systolic shortening; n ϭ 7 for each treatment group. low-dose HGF had significantly lower VFRF, higher CD, and shorter ODD compared with sham-operated controls. Compared with controls, the high-dose HGF group showed significantly less VFRF, less VFIF, greater CD, and significantly shorter ODD and lower MCSA (Table 6 and Fig. 3) .
Effects of HGF on calcium cycling protein. The percent change from normal dogs of protein expression of SERCA-2a, PLB, RyR, and CSQ in LV anterior and posterior walls is shown in Table 7 , and protein bands are shown in Fig. 4 . Protein expression of CSQ, a housekeeping protein, was unchanged among the three study groups. The protein levels of SERCA-2a, PLB, and RyR decreased significantly in shamoperated control dogs compared with normal dogs. Both low and high doses of HGF significantly increased the expression of SERCA-2a, PLB, and RyR in the anterior wall only. P-PLB16 in tissue obtained from both LV anterior and posterior walls was significantly lower in sham-operated HF dogs compared with normal dogs. P-PLB17 decreased in sham-operated control dogs in both LV anterior and posterior walls, but the decrease was only significant in the posterior wall. The expression of P-PLB16 improved significantly after high-dose HGF in both LV anterior and posterior walls, whereas expression improved significantly after low-dose HGF in the anterior wall only. No significant change was seen in the expression of P-PLB17 after treatment with low-or high-dose HGF compared with controls ( Table 7) .
Effects of HGF on apoptosis regulating genes. A formal statistical analysis was not performed on mRNA expression results due to the small sample size (n ϭ 3). Results of mRNA expression studies are shown in Table 8 . mRNA expression of GAPDH was unchanged among the three study groups. Expression of caspase-3 and BAX tended to increase in shamoperated controls compared with normal dogs. Both low-and high-dose HGF decreased the expression of BAX, whereas the expression of caspase-3 tended to decrease with low-and high-dose HGF in the anterior wall only. Expression of PARP and BCL2 tended to decrease in sham-operated controls compared with normal dogs. High-dose HGF increased the expression of PARP and BCL2 in the anterior wall only (Table 8 ).
DISCUSSION
Many of the studies reported to date that explored the effects of HGF on the diseased myocardium have focused on the benefits of this potential therapy in the setting of AMI, chronic ischemia, and, to a lesser extent, hereditary cardiomyopathy. The present study expands on these observations by exploring the benefits of HGF in chronic HF and the potential for this therapeutic approach to favorably impact the time course of progressive LV dysfunction and remodeling that are characteristic of the HF state.
The results of this study indicate that in dogs with moderate HF, localized intramyocardial injections of high-dose HGF naked DNA plasmid improve regional as well as global LV Values are means Ϯ SE of protein expression as %change from normal; n ϭ 7 for each treatment group. LD, low dose; HD, high dose; CSQ, calsequestrin; SERCA-2a, sarco(endo)plasmic reticulum calcium ATPase-2a; PLB, phospholamban; RyR, ryanodine receptor; P-PLB, phosphorylated PLB at serine 16 (PLB16) or at threonine 17 (PLB17); P-RyR, phosphorylated RyR. *P Ͻ 0.05 vs. normal. †P Ͻ 0.05 vs. control. function and prevent progressive LV chamber remodeling. This observation is supported by the finding that high-dose HGF delivered in the LV anterior wall increased LV EF, FAS, and DT and decreased LV ESV, EDP, and EDWS. These global benefits extended to the cellular level as evidenced by improvement of the SR Ca 2ϩ -regulatory proteins, attenuation of replacement and interstitial fibrosis, reduced cardiomyocyte hypertrophy, and overall improvement in oxygen supply to the contractile units, evidenced by increased CD and reduced ODD. All these favorable observations provide support for the concept that treatment with HGF plasmid prevents progressive worsening of the HF state.
Effects of HGF on LV function and global remodeling. The observation of preserved cardiac function and attenuation of LV global remodeling in dogs randomized to receive HGF is in agreement with previous studies of HGF in experimental models of myocardial disease. Therapy with HGF tended to protect cardiomyocytes during myocardial infarction (13, 24) , and survival of cardiomyocytes was enhanced under conditions of elevated oxidative stress (9, 24) . Other studies also have shown that HGF has beneficial effects on cardiac function in animal models of chronic ischemic and hereditary cardiomyopathy (10, 12, 23) . In these studies, the improvement in cardiac function was attributed to antifibrotic, antihypertrophic, and angiogenic actions. In patients with AMI, enhanced secretion of cardiac HGF from the infarcted region was associated with less severe LV enlargement and improved LV function, a finding suggestive of a role of HGF in modulating the process of LV remodeling (25) . Consistent with this clinical observation is the finding in the present study of improved LV wall motion in LV wall segments in which HGF was administered but continued depressed function in the segments that did not receive HGF.
Effects of HGF on myocardial fibrosis, cardiomyocyte hypertrophy, and apoptosis. Structural maladaptations such as cardiomyocyte hypertrophy and accumulation of collagen in the cardiac interstitium occur in HF and can lead to LV diastolic dysfunction (19, 22) . In the present study, VFIF, VFRF, and MCSA, a measure of cardiac hypertrophy, were significantly reduced in dogs treated with high-dose HGF compared with controls, consistent with results of other experimental studies (8, 12, 23) . These effects of HGF may be explained in part by its antagonistic effect on transforming growth factor-␤1 (TGF-␤1). TGF-␤1 is one of the most important mediators of the profibrogenic actions of angiotensin II (ANG II) in cardiac remodeling (5, 12) , and both ANG II and TGF-␤1 are strong negative regulators of local HGF production and activity (14) . ANG II increases expression of TGF-␤1 in cardiac fibroblasts, and in turn, TGF-␤1 acts on fibroblasts to increase extracellular matrix deposition and mediate their differentiation into myofibroblasts (12) . Interestingly, in experimental cardiomyopathic models, pharmacological interventions with either ACE inhibitors or ANG II type I receptor antagonists have been demonstrated to stimulate cardiac HGF expression and production, resulting in decreased fibrosis and improved contractile function (11, 23) . HGF also has been shown to possess a host of properties that include antiapoptotic effects (12) . Cardiomyocyte apoptosis occurs in HF and may be partly responsible for the progressive worsening of LV function characteristic of the HF state. In the present study, therapy with HGF was associated with reduced expression of the proapoptosis genes caspase-3, PARP, and BAX and increased expression of the antiapoptosis gene BCL2. Alleviation of this apoptotic burden may have contributed, albeit in part, to the recovery of LV function following therapy with HGF.
Effects of HGF on angiogenesis. A decrease in CD, a measure of number of capillaries, and an increase in ODD frequently accompany reactive interstitial fibrosis and hypertrophy in the setting of HF (19) . In the present study, CD was significantly increased and ODD was significantly shortened in dogs treated with HGF compared with controls. The increase in CD and shortened ODD observed in the present study may be attributed to the proangiogenic activity of HGF. In the present study, increased expression of HGF in the LV anterior wall was detectable at 2 wk after intramyocardial injections. We did Values are means Ϯ SE of mRNA expression as %change from normal; n ϭ 3 for each treatment group. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PARP, poly(ADP-ribose) polymerase. not conduct HGF expression studies beyond this time point. Nonetheless, increased expression of at least 2 wk has been shown to markedly promote angiogenesis (1). Our results are in agreement with studies conducted in other animal models of AMI and HF. Angiogenic and antifibrotic actions of HGF were implicated in the improvement of cardiac function in ischemic myocardium of pigs (3) . In dogs with pacing-induced HF, gene transfection of HGF promoted angiogenesis and decreased fibrosis (1) . Studies in Syrian cardiomyopathic hamsters and in ischemic rats showed that HGF gene transfer may have cardioprotective effects mediated through antifibrotic and proangiogenic actions (8, 23) .
Effects of HGF on the SR Ca 2ϩ -regulatory proteins. In failing hearts of animals and humans, protein expression of the SR Ca 2ϩ -regulatory genes is altered. The results of this study demonstrate that treatment of the failing heart with HGF improves expression of SR Ca 2ϩ -handling proteins. In the failing heart, expression of SERCA-2a, PLB, and RyR was decreased. We have previously shown a reduced level of P-PLB17 and P-PLB16 in HF (5a, 6). Both of these modulate SERCA-2a activity and are responsible for reduced SR Ca 2ϩ uptake. Results of the present study suggest that normalization of these proteins by HGF treatment might be responsible for improving calcium homeostasis in the failing cardiomyocytes and, in turn, LV function. It is also possible, however, that the improvement in expression of SR protein is partly an indirect reflection of the overall improvement in global LV function. The observation of increased expression of PLB and P-PLB16 in the LV posterior wall tends to support this alternative explanation.
Conclusions. Results of the present study indicate that intramyocardial injections of HGF in dogs with moderate HF prevent progressive LV dysfunction and attenuate global and structural LV myocardial remodeling. The results of the present study provide a biological rationale for the potential use of HGF transfection therapy in patients with HF.
